Institute of Pharmacology and Neurotherapeutics
Developing Next-Generation Therapies for Brain Diseases
Brain diseases affect about 500 million people worldwide, including roughly 25 percent of the U.S. population, and many are disabled due to lack of effective therapies. The Texas A&M Health Institute of Pharmacology and Neurotherapeutics (IPN) harnesses the power of multidisciplinary team science to address the urgent need for developing therapies for brain diseases.
Leveraging the Power of Team Science
Our key goal is to promote and accelerate the search for therapies for neurological conditions and advance education and training in neurotherapeutics research.
We forge partnerships and build synergies among brain scientists, biomedical engineers, neural machine learning researchers, and clinical and regulatory technologists. Such collaborations are crucial for successful development of next-generation neurotherapies.
Education & Training
We provide a number of courses, workshops, training programs and research projects that advance the education and training of researchers to diversify the workforce in neurotherapeutics research.
Research
The institute features a world-class group of investigators with extensive expertise in pharmacology and neurotherapeutics.
Impact
Brain disorders affect nearly a quarter of the U.S. population and cost the U.S. economy more than $1.5 trillion per year. Emerging neural technologies have unprecedented potential for a new revolution in neurotherapeutics.
News & Publications
See the latest news, scientific publications and reports from the institute.
Research Resources
TAMU Proposal Support
Proposal Support
TAMU Research Cores and Resources
Research Resources
TAMHSC Research Resources
Cutting-edge research that improves human health
Donate to IPN
IPN programs are supported by extramural and internal support. Donations, gifts and endowments are welcome to advance IPN research.
Contact IPN Director Dr. Samba Reddy
sambareddy@tamu.edu
Tel: 979-436-0324
Forums
Acute Neuronal Injuries
- Stroke
- Spinal cord injury
- Traumatic brain injury
- Chemical neurotoxicity
- Infection encephalitis
Chronic Neurological Diseases
- Epilepsy
- Migraine and spasticity
- Parkinson’s disease
- Alzheimer’s disease
- Neuropathic pain
- Genetic syndromes
- Glioblastoma and brain tumors
Drug Abuse and Neuropsychiatric Diseases
- Drug and alcohol addiction
- Autism, ADHD, PTSD
- Anxiety and sleep disorders
- Mood disorders
- Schizophrenia
Neurostimulation
- Deep Brain Stimulation
- Spinal Cord Stimulation
- Electroceuticals
Pharmacotherapeutics & Clinical Trials
- Formulation and Development
- 3D Printing and Drug Delivery System
- Controlled Release Products
- Vaccine and Biologicals
- GMP Pharmaceuticals